Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors at 1 institution in 1 country.
Debbie PiktelWest Virginia University Cancer Institute, Robert C. Byrd Health Sciences Center, West Virginia University, Morgantown, WV 26506, USA.ORCID 0000-0001-6706-5923
Javohn C MooreWest Virginia University Cancer Institute, Robert C. Byrd Health Sciences Center, West Virginia University, Morgantown, WV 26506, USA.
Sloan NesbitWest Virginia University Cancer Institute, Robert C. Byrd Health Sciences Center, West Virginia University, Morgantown, WV 26506, USA.
Samuel A SprowlsDepartment of Pharmaceutical Sciences, West Virginia University School of Pharmacy, Morgantown, WV 26506, USA.ORCID 0000-0003-1995-0586
Michael D CraigWest Virginia University Cancer Institute, Robert C. Byrd Health Sciences Center, West Virginia University, Morgantown, WV 26506, USA.
Stephanie L RellickWest Virginia University Cancer Institute, Robert C. Byrd Health Sciences Center, West Virginia University, Morgantown, WV 26506, USA.
Rajesh R NairWest Virginia University Cancer Institute, Robert C. Byrd Health Sciences Center, West Virginia University, Morgantown, WV 26506, USA.
Ethan MeadowsDepartment of Physiology and Pharmacology, School of Medicine, West Virginia University, Morgantown, WV 26506, USA.ORCID 0000-0001-9633-7596
John M HollanderDepartment of Physiology and Pharmacology, School of Medicine, West Virginia University, Morgantown, WV 26506, USA.
Werner J GeldenhuysDepartment of Pharmaceutical Sciences, West Virginia University School of Pharmacy, Morgantown, WV 26506, USA.ORCID 0000-0002-2405-376X
Karen H MartinWest Virginia University Cancer Institute, Robert C. Byrd Health Sciences Center, West Virginia University, Morgantown, WV 26506, USA.ORCID 0000-0001-8916-4092
Laura F GibsonWest Virginia University Cancer Institute, Robert C. Byrd Health Sciences Center, West Virginia University, Morgantown, WV 26506, USA.
West Virginia University · US
Funding
West Virginia IDEA-CTRU54GM104942 · NIGMS · WEST VIRGINIA UNIVERSITY · PI Sally Lynn Hodder · 2012 to 2026
$81.0M
WV INBRE: The Inhibitor of Growth Family Member 4 (ING4) inhibits L-Type Amino Acid Transporter 1 (LAT1) expression to suppress Breast CancerP20GM103434 · NIGMS · MARSHALL UNIVERSITY · PI Trupti Joshi · 2012 to 2026
$61.1M
West Virginia University Stroke COBREP20GM109098 · NIGMS · WEST VIRGINIA UNIVERSITY · PI DEVRIES, ANNE COURTNEY · 2014 to 2024
$24.5M
THE ROLE OF HEF1 PROTEIN IN INVASION OF METASTATIC BREAST CANCERP20RR016440 · NCRR · WEST VIRGINIA UNIVERSITY · PI HARNER, JAMES · 2001 to 2010
$22.8M
WVU Flow Cytometry and Single Cell Core Facility (FCSCCF)P20GM121322 · NIGMS · WEST VIRGINIA UNIVERSITY · PI Karen H Martin · 2018 to 2026
$22.4M
West Virginia Flow Cytometry Core FacilityP30GM103488 · NIGMS · WEST VIRGINIA UNIVERSITY · PI CUFF, CHRISTOPHER F · 2012 to 2016
$4.8M
miRNA Regulation of the Mitochondrial GenomeR01HL128485 · NHLBI · WEST VIRGINIA UNIVERSITY · PI HOLLANDER, JOHN M · 2017 to 2019
$1.3M
miRNA Regulation of the Mitochondrial GenomeR56HL128485 · NHLBI · WEST VIRGINIA UNIVERSITY · PI HOLLANDER, JOHN M · 2015 to 2015
$410k
Special Becton Dickinson Fortessa Flow CytometerS10OD016165 · OD · WEST VIRGINIA UNIVERSITY · PI CUFF, CHRISTOPHER F · 2013 to 2013
$384k
Sex Differences in Blood-Brain and Blood-Tumor Barrier Dynamics in GlioblastomaK00CA253768 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SPROWLS, SAMUEL ADAM TYLER · 2022 to 2024
B-cell acute lymphoblastic leukemia (ALL) is derived from an accumulation of malignant, immature B cells in the bone marrow and blood. Relapse due, in part, to the emergence of tumor cells that are resistant to front line standard chemotherapy is associated with poor patient outcomes. This challenge highlights the need for new treatment strategies to eliminate residual chemoresistant tumor cells. Based on the use of pitavastatin in acute myeloid leukemia (AML), we evaluated its efficacy in an REH ALL cell line derived to be resistant to vincristine. We found that pitavastatin inhibited the proliferation of both parental and vincristine-resistant REH tumor cells at an IC
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Chemotherapeutic Activity of Pitavastatin in Vincristine Resistant B-Cell Acute Lymphoblastic Leukemia. · full record | OpenQuestion